Search
Rurioctocog alfa pegol
go.drugbank.com/drugs/DB16007ApprovedInvestigationalIt was first approved by the European Commission in January 2018. … [L40119] Rurioctocog alfa pegol is a covalent conjugate of [octocog alfa], which is a recombinant factor VIII produced by recombinant DNA technology from a Chinese hamster ovary cell line.
Carbamoylcholine
go.drugbank.com/drugs/DB00411ApprovedCarbamoylcholine was granted FDA approval on 28 September 1972.[L30245] … Carbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932.
Categories: Compounds used in a research, industrial, or household settingFibrinogen human
go.drugbank.com/drugs/DB09222ApprovedInvestigationalIt works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting. … It is indicated for the treatment of acute bleeding episodes in patients with both acquired and congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.[L41065]
Mixtures: PAZ. SAN. VE TİC. LTD.Technetium Tc-99m succimer
go.drugbank.com/drugs/DB09436Approved[L40558] The use of technetium Tc-99m succimer for the detection of kidney cortical defects was first approved by the FDA on February 23, 2022, under the market name NephroScan.[L40573] … function in patients with renal parenchymal disorders.
Categories: Compounds used in a research, industrial, or household settingThiosulfuric acid
go.drugbank.com/drugs/DB09499ApprovedInvestigational[A252827] Sodium thiosulfate is rapidly degraded in the stomach; therefore, it is normally administered through other routes, such as intravenous or topical. … Thiosulfuric acid is available in its salt forms sodium thiosulfate and sodium thiosulfate pentahydrate.
Categories: Compounds used in a research, industrial, or household settingAbaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized
Probenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalProbenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
Categories: Preparations With No Effect on Uric Acid Metabolism, Compounds used in a research, industrial, or household settingSynonyms: 4-(N,N-Dipropylsulfamoyl)benzoesäure, 4-(Di-n-propylsulfamoyl)benzoesäureEftrenonacog alfa
go.drugbank.com/drugs/DB11608ApprovedIt is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H … Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.
Temsirolimus
go.drugbank.com/drugs/DB06287ApprovedInvestigationalTemsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007. … Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel.
Maftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Maftivimab (REGN 3479), [Odesivimab] (REGN 3471), and [Atoltivimab] (REGN 3470) in equimolar proportions